OmniAb, Inc. (OABI): Depreciation & Amortization
$21.75M
Year ended 2025-12-31
+6.0%
3-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $21.75M | -7.8% | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | $23.58M | +21.0% | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | $19.50M | +6.8% | 2025-03-18, From 2023-01-01 |
| 2022-12-31 | $18.25M | +12.3% | 2024-03-25, From 2022-01-01 |
| 2021-12-31 | $16.25M | n/a | 2023-03-30, From 2021-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| OmniAb, Inc. (OABI) | 2025-12-31 | $21.75M | -7.8% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $597.4K | -51.6% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $4.34M | +0.6% |
| bioAffinity Technologies, Inc. (BIAF) | 2025-12-31 | $504.8K | -16.6% |
| Absci Corp (ABSI) | 2025-12-31 | $11.74M | -12.3% |
| NRC Health (NRC) | 2025-12-31 | $7.62M | +26.6% |
| iSpecimen Inc. (ISPC) | 2025-12-31 | $1.73M | -24.6% |
| OneMedNet Corp (ONMD) | 2025-12-31 | $65.0K | +14.0% |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $403.31M | +11.5% |
Compare OABI, FOXO, MXCT, BIAF side by side · Screen every company in Services-Commercial Physical & Biological Research ↗